---
title: rTMS-induced Cumulative Pattern of sBDNF in Chronic Schizophrenia
nct_id: NCT01427088
overall_status: COMPLETED
phase: NA
sponsor: Jeonbuk Provincial Maeumsarang Hospital
study_type: INTERVENTIONAL
primary_condition: Schizophrenia
countries: South Korea
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT01427088.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT01427088"
ct_last_update_post_date: 2015-02-18
last_seen_at: "2026-05-12T06:15:05.085Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# rTMS-induced Cumulative Pattern of sBDNF in Chronic Schizophrenia

**Official Title:** Short-Term Response of Serum Brain-Derived Neurotrophic Factor to Repetitive Transcranial Magnetic Stimulation in Patients With Chronic Schizophrenia

**NCT ID:** [NCT01427088](https://clinicaltrials.gov/study/NCT01427088)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 21
- **Lead Sponsor:** Jeonbuk Provincial Maeumsarang Hospital
- **Conditions:** Schizophrenia
- **Start Date:** 2011-08
- **Completion Date:** 2011-11
- **CT.gov Last Update:** 2015-02-18

## Brief Summary

This study aims at investigating the neuroplastic potential and the possible factors affecting rehabilitation in chronic schizophrenia patients on stable medication, by investigating the cumulative pattern of serum BDNF representing the neuroplasticity in the brain, through quantitative stimulus such as rTMS.

## Detailed Description

Subjects who have been enrolled for this study will take baseline evaluation for sociodemographic data and serum level of BDNF, plasma Prolaction, and magnesium, etc. And then, weekday regular stimulation through rTMS will be applied on DLPFC of brain. After the completion of stimulation for 2 weeks, the change or response of serum BDNF will be analyzed and compared.

## Eligibility

- **Minimum age:** 25 Years
- **Maximum age:** 60 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* duration of illness over 10 years
* on stable medication, antipsychotics
* no change on medication within at least 2 weeks
* Diagnosis of Schizophrenia according to DSM-IV-TR

Exclusion Criteria:

* left or both-handedness
* anticonvulsant use
* lorazepam equivalent over 3 mg
```

## Arms

- **repetitive TMS** (EXPERIMENTAL) — repetitive TMS is a quantified stimulation method of specifie area of brain, for which CR Technology, TAMAS for repetitive TMS was used.

## Interventions

- **CR Technology, TAMAS for repetitive TMS** (DEVICE) — repetitive TMS, lef DLPFC, 20Hz, 100% of MEP, 2weeks

## Primary Outcomes

- **change from baseline of serum BDNF concentration** _(time frame: baseline-1 week-2 week-4 week)_

## Locations (1)

- Jeonbuk Provincial Maeumsarang Hospital, Wanju, Jeollabuk-do, South Korea

## Recent Field Changes (last 30 days)

- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `locations.jeonbuk provincial maeumsarang hospital|wanju|jeollabuk-do|south korea` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT01427088.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT01427088*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*